BACKGROUND: Pediatric oncology patients are at an increased risk of invasive bacterial infection due to immunosuppression. The risk of such infection in the absence of severe neutropenia (absolute neutrophil count 500/lL) is not well established and a validated prediction model for blood stream infection (BSI) risk offers clinical usefulness. METHODS: A 6-site retrospective external validation was conducted using a previously published risk prediction model for BSI in febrile pediatric oncology patients without severe neutropenia: the Esbenshade/Vanderbilt (EsVan) model. A reduced model (EsVan2) excluding 2 less clinically reliable variables also was created using the initial EsVan model derivative cohort, and was validated using all 5 external validation cohorts. One data set was used only in sensitivity analyses due to missing some variables. RESULTS: From the 5 primary data sets, there were a total of 1197 febrile episodes and 76 episodes of bacteremia. The overall C statistic for predicting bacteremia was 0.695, with a calibration slope of 0.50 for the original model and a calibration slope of 1.0 when recalibration was applied to the model. The model performed better in predicting high-risk bacteremia (gram-negative or Staphylococcus aureus infection) versus BSI alone, with a C statistic of 0.801 and a calibration slope of 0.65. The EsVan2 model outperformed the EsVan model across data sets with a C statistic of 0.733 for predicting BSI and a C statistic of 0.841 for high-risk BSI. CONCLUSIONS: The results of this external validation demonstrated that the EsVan and EsVan2 models are able to predict BSI across multiple performance sites and, once validated and implemented prospectively, could assist in decision making in clinical practice. Cancer 2017;123:3781-90.
INTRODUCTION
Due to immune suppression from cancer and its treatment, pediatric oncology patients are at risk of bacterial blood stream infections (BSIs), particularly in the setting of indwelling central venous catheters (CVCs) . 1 There are evidence-based guidelines supporting empiric broad-spectrum antibiotics in these patients for fever occurring within the setting of an absolute neutrophil count (ANC) < 500/lL.
1 However, to the best of our knowledge, there is little evidence-based data to guide the optimal management for patients with fever and an ANC 500/lL. [2] [3] [4] [5] The Esbenshade/Vanderbilt (EsVan) predictive model was created to predict the likelihood of BSI in pediatric patients with cancer with an ANC 500/lL. 4 However, as a model developed in a single institution, it requires external validation before implementation in evidencebased clinical care. Therefore, using 3 previously published data sets and 3 newly created data sets, we sought to externally validate the EsVan model and to evaluate its performance to provide evidence to support its implementation in clinical practice.
MATERIALS AND METHODS

Original Model
The EsVan model was based on 932 febrile pediatric oncology subjects with an ANC 500/lL with the purpose of identifying clinical variables that can help to predict the likelihood of BSI. 4 The variables, which all were assessed at time of presentation, and were determined to increase the risk of a BSI were tunneled external catheters, highest temperature reported or measured within 24 hours before presentation or within 1 hour after presentation, reported or observed chills, hypotension, and increased ANC. Factors associated with a decreased risk of BSI were exposure to chemotherapy drugs that cause fever (ie, cytarabine, antithymocyte globulin, and anti-GD2 antibody therapy) within 24 hours of the fever, older age, and a diagnosis of acute lymphoblastic leukemia (ALL). Other factors included in the model were location at the time of presentation (inpatient vs outpatient), presence of upper respiratory symptoms (cough, congestion, or rhinorrhea mentioned in the medical record), and a history of stem cell transplantation. This model performed very well, with a C statistic of 0.898. 4 The formula of the original logistic regression prediction model is shown in Supporting Information Figure 1 , and a Web-based module can be accessed at https://cqs.mc.vanderbilt.edu/shiny/ RiskPrediction/.
Inclusion and Exclusion Criteria for the Model
Episodes to be included in a data set for external validation of the EsVan model followed the same inclusion criteria previously established for the EsVan predictive model: fever 38.0 8C for > 1 hour or 38.3 8C for any duration, in agreement with the 2010 Infectious Diseases Society of America guidelines update 6, 7 ; CVC; and an ANC 500/lL at the time of presentation. 4 Exclusion criteria included events occurring within 7 days of a previous febrile episode to prevent the possibility of fever episodes being linked, during administration of empiric/treatment antibiotics for previous fever or an infection, or within 30 days after a stem cell transplantation. Pediatric oncology subjects were defined as anyone aged <23 years at the time of diagnosis with a diagnosis of cancer, Langerhans cell histiocytosis, or hemophagocytic lymphohistiocytosis.
Construction of the Validation Cohort
To validate the EsVan model, 6 external data sets were obtained that met the inclusion and exclusion criteria. This included 3 previously published data sets and 3 data sets that were constructed specifically for the validation cohort. For those data sets that were previously published, local investigators used additional medical record review to document all inclusion criteria and delete those cases meeting exclusion criteria. Bartholomew et al published a data set of 392 episodes of pediatric nonneutropenic fever. 3 After applying EsVan inclusion and exclusion criteria, this resulted in a cohort of 348 episodes, 312 of which had complete data and were used for the primary analysis with the additional episodes to be included in the sensitivity analysis. Ali et al published a data set of 254 episodes of nonneutropenic fever, all of which met the inclusion/exclusion criteria, and therefore a deidentified data set was presented for analysis. 2 Kelly et al previously published a data set of 459 episodes of pediatric nonneutropenic fever and provided a deidentified spreadsheet of the initial data set. 5 Due to more limited variables available, this data set was used only for the sensitivity analysis. Three additional data sets were constructed for the external validation study. These included 209 episodes from Columbia University from 2009 through 2012, 193 episodes from Children's Hospital of Philadelphia (CHOP) from 2011 through 2015, and 229 episodes from the University of California at San Francisco (UCSF) from 2012 through 2014. The Columbia University data set consisted of all nonneutropenic patients who presented to their clinic or emergency room in the outpatient setting; at UCSF, the data set comprised all patients who presented to their institution with nonneutropenic fever in all settings. The CHOP data set was unique because it was the only one that did not include all subjects diagnosed during a specific time frame. Instead, the CHOP data set identified all patients presenting to the clinic during one specific week and abstracted all the events that occurred among those subjects from 2011 through 2015. All 5 primary data sets with complete data together resulted in a total cohort of 1197 episodes. When all 6 data sets were combined, including missing data for use in the primary sensitivity analysis, the total cohort was 1692 episodes. Table 1 summarizes the original EsVan data set and the 6 data sets used in the external validation.
Outcome
The EsVan model was designed to predict the outcome of isolated BSI and thus this outcome was maintained in the external validation, using the same criteria. A BSI was Original Article 10.9% (25) 3.6% (7) 3.3% (7) 3.1% (8) 6.3% (29)
Age at time of episode (5) 3.3% (7) 7.5% (19) NA e Hypotension 1.7% (16) 4.3% (52)
<.001 b 6.7% (21) 6.6% (15) 3.6% (7) 2.9% (6) 1.2% (3) 1.8% (7) e Drug exposure 35.3% (110) 67.7% (155) 53.4% (103) 0% (0) 0% (0) 0% (0) Outpatient 80.5% (750) 69.3% (829) 64.7% (202) 32.3% (74) 46.6% (90) 100% (209) 100% (254) 100% ( Information regarding chills, drug exposure, and history of stem cell transplantation was not available for this data set and information regarding hypotension was available for 388 in this data set.
f Exposure to cytarabine, neuroblastoma antibody therapy (anti-GD2), or antithymocyte globulin (ATG) within 24 hours of presentation.
g Cough, rhinorrhea, and/or congestion.
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October 1, 2017 defined previously as 1 positive blood culture for bacteria obtained from a CVC for a recognized pathogen at the time of fever. For certain common commensals (coagulase-negative staphylococci [CoNS] , viridans group streptococci, diphtheroids, Micrococcus, or Bacillus species), 2 positive blood cultures were required to meet criteria for BSI. 8, 9 Any of these bacterial isolates recovered from a single blood culture with a corresponding negative preantibiotic culture drawn were classified in the analysis as non-BSI, and those cases in which there was only one preantibiotic culture drawn were excluded from the analysis due to inadequate data with which to assess a true versus false-positive BSI. High-risk BSIs were defined as those with a high risk of sepsis or other complications (gram-negative organism or Staphylococcus aureus). Because there were no isolated fungal BSIs in the original Vanderbilt model and fungal infections are not sensitive to antibiotics, all isolated fungal infections were classified as non-BSI.
Statistical Analysis
The demographic and clinical variables of the patients were summarized by study cohort. For continuous variables, the median and lower and upper quantiles were reported. The differences between the EsVan cohort and the validation cohorts were assessed using the Wilcoxon rank sum test. For categorical variables, the frequencies with percentages were reported, and the differences were assessed using the Pearson chi-square test.
To evaluate the performance of the EsVan model in the independent validation cohorts, model discrimination and calibration were assessed. Discrimination measures the ability of the model to differentiate between patients with and without the outcome event. It generally is quantified using the area under the receiver operating characteristic curve, which is equivalent to the Harrell C statistic. [10] [11] [12] The C statistic of the EsVan model on the validation cohort was compared with the benchmark C statistic, which is the best possible C statistic derived by refitting the model on the validation data set. The 95% confidence intervals (95% CIs) calculated from 300-iteration bootstraps also were reported. Calibration measures the agreement between observed outcomes and predictions. Calibration most commonly is assessed graphically with a calibration plot. The calibration plot has predictions on the x-axis and the outcome on the yaxis. Perfect prediction should be on the 45-degree line. For binary outcomes, the plot contains only 0 and 1 values for the y-axis. Smoothing techniques generally are used to estimate the observed probabilities of the outcome in relation to the predicted probabilities (eg, using the LOESS algorithm). 13 The recalibration was conducted using the logistic method, in which a logistic regression model was fitted using the linear predictors (from the original model) as the only covariates. The updated calibration slopes and intercepts were reported. 14, 15 The primary validation data set (1197 episodes) included all data set information from which full model variables were available. The model performance was assessed for both BSI and high-risk BSI. The variables used in the original EsVan model were determined a priori. Because the EsVan model uses a large number of variables, penalized maximum likelihood estimations were used in the logistic regression to avoid overfitting. To account for the potential correlation among multiple episodes observed from the same individual, the robust covariance matrix estimates using the Huber-White method were used. 16, 17 More detailed methods have been described in the original article. 4 In the current validation study, we primarily combined all the external data sets into a master external data set for the purposes of more precisely assessing the model performance. Individual strict validation data are given for each institution to provide an estimate of how the model performed across institutions, although the estimates generally are associated with less precision due to the smaller number of events. The TRIPOD (Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) checklist for prediction model validation studies was applied.
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With the goal of external validation, the variables were reconsidered. Previously, an ALL diagnosis initially was included in EsVan model, given the hypothesis that the majority of patients with ALL were at a lower risk of BSI. However, it subsequently was noted that this was dependent on the phase and type of ALL therapy, with, for example, subjects with recurrent ALL noted to be at high risk of BSI. 19 Location at the time of presentation also was included in the original EsVan model because it was hypothesized that subjects who were inpatients for chemotherapy were less likely to develop a BSI compared with subjects in the community. However, this was dependent on the patient population and, with differing admission criteria noted across centers, was thought not to be a reliable risk factor that could be used in a more universal model. Thus, a more parsimonious reduced EsVan2 model was created. This reduced model then was applied to the primary validation data set and discrimination and calibration again were assessed. A nomogram for the reduced EsVan2 model is shown in Figure 1 , and a Webbased module also can be accessed at https://cqs.mc.
vanderbilt.edu/shiny/RiskPrediction/. Because an absolute monocyte count (AMC) can be challenging for some institutions to assess quickly at the time of presentation, a version of the reduced model (EsVan2b) also was created that eliminated AMC as a variable.
Finally, sensitivity analyses were conducted in which all models were applied to the larger validation data set that included those with missing data (1692 episodes). For missing data, all missing variables were set first conservatively to "no" and then to "yes" (hypotension, chills, stem cell transplantation, and upper respiratory symptoms) and the models were applied.
All statistical significance was considered at a 2-sided 5% level. All statistical analyses were performed using R software (version 3.3.1; R Foundation for Statistical Computing, Vienna, Austria). 20 
RESULTS
Patient Characteristics
The demographics and clinical features of the external validation cohort as well as the original EsVan derivation cohort are shown in Table 1 . Statistically significant differences between the external and the EsVan derivation cohorts were noted with regard to BSI rate (6.1% vs 9.8%; P 5 .002), AMC (400/ll vs 460/ll; P<.001), type of central line present (P<.001), chills by history or observation (7.9% vs 11.8%; P 5 .002), hypotension (4.3% vs 1.7%; P<.001), upper respiratory symptoms (34.3% vs 45%; P<.001), history of stem cell transplantation (13.8% vs 7.1%; P<.001), location at the time of presentation (30.7% vs 19.5%; P<.001), and diagnosis of ALL (42.1% vs 47.9%; P 5 .008). There were 17 suspected contaminants: a total of 14 cases were CoNS and 2 were Bacillus across the external data sets that were able to be reclassified as non-BSI and only 1 case of CoNS was excluded due to only having 1 preantibiotic culture. There also were a total of 3 fungal isolates across the external data sets that were classified as non-BSI. The specific microbiologic organisms isolated at each site are provided (see Supporting Information Table 1 ).
Primary Validation of the EsVan Model
When the original EsVan model was applied to the primary external validation cohort, it demonstrated reasonable discrimination, with a C statistic of 0.695 (95% CI, 0.633-0.762) ( Fig. 2A) , and a benchmark C statistic of this model refitted on the validation cohort of 0.759. The model calibrated well, particularly for those patients with a low predicted risk of developing BSI (Fig. 2B) . After recalibration, the model achieved an intercept of 0 and slope of 1 (Fig. 2C) . In predicting high-risk BSI, the model performed better, with a C statistic of 0.801 (95% CI, 0.693-0.894) (see Supporting Information Fig. 2A) , and the calibration plot is shown in Supporting Information Figure 2B (Fig. 3A) , with a Fig. 2C) . The calibration is shown in Supporting Information Figure 2D . When AMC also was removed from the EsVan2 model, the C statistic for the EsVan2b model on the external validation cohort fell to 0.731 for BSI and 0.832 for high-risk BSI. Using the external data sets, Figure 4 provides a distribution for the predicted probability from the model for each episode of non-high-risk BSI and high-risk bacteremia. This demonstrated that approximately 85.1% of the cases were low risk (<10% predicted risk), with the BSI rate in that group being 4.3% with only 27.9% of the BSI infections in that group being high risk. There also was an increase in actual BSI rates in those with a predicted risk >40%, with an actual BSI rate of 35% noted in these subjects.
Sensitivity Analysis
When the EsVan model was applied to the secondary data set with all missing values set conservatively to "no," it demonstrated a C statistic for BSI of 0.678 and a C statistic for high-risk BSI of 0.781. For the updated reduced model, the EsVan2 model, the C statistic was 0.711 for BSI and 0.800 for high-risk BSI. When the EsVan model was applied to the secondary data set with all missing values set to "yes," it demonstrated a C statistic for BSI of 0.672 and a C statistic for high-risk BSI of 0.759. For the updated reduced model, the EsVan2 model, the C statistic was 0.690 for BSI and 0.757 for high-risk BSI. Because the results from these very conservative approaches were quite similar, further multiple imputation methods on the missing values were not attempted (see Supporting Information Fig. 4 ).
Strict Application of the Model to the Individual Data Sets
When applied strictly to each data set, the EsVan model showed the following C statistics: 0.705 for UCSF, 0.738 for Stanford, 0.725 for Columbia, 0.483 for the 
DISCUSSION
To the best of our knowledge, the EsVan model is the first to attempt to predict BSI in febrile pediatric oncology subjects without severe neutropenia, and the current study externally validated this model by demonstrating that in applying it to new data sets, it still was able to show good discrimination in predicting BSI (C statistic of 0.695), with improved discrimination for high-risk BSI (C statistic of 0.801). Compared with the C statistic from the initial model derivation cohort, there was a small decrease in the C statistic in this validation cohort. This may be due to the differences in the case mix between this validation cohort and the initial derivation cohort. The validation cohort in the current study had a significantly lower BSI incidence, and was different from the initial derivation cohort with regard to several patient characteristics. However, it is worth noting that when we refit the model on the validation cohort, the benchmark C statistic rose from nearly 0.70 to 0.76, indicating that the EsVan model performed reasonably to the best possible model that one can achieve from this particular validation cohort.
Overall, the EsVan model also demonstrated good calibration in the validation cohort in the current study, although the upper tail of the curve was not calibrated perfectly in that it was found to overpredict the risk of BSI in those with a risk >40% (the actual BSI rate was 35% in these subjects). However, the model was quite good for patients with a predicted BSI risk <10%, which was 85% of the cohort. 4 It has been suggested that when applied to a new data set, a model should be recalibrated so that the calibration and predictions become more accurate in the new population, while preserving discrimination. 15, 21 When the EsVan model was recalibrated on the validation cohort in the current study, its performance improved and it achieved a calibration intercept of 0 and a slope of 1 (Fig. 2B) , further demonstrating the usefulness of the model. For other institutions to use this model, the performance and prediction accuracy potentially could be improved by updating the model with local institutional data, although the EsVan model did demonstrate relatively good calibration and therefore could be directly adapted and used in a clinical setting.
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The EsVan2 model was created to assess whether reduction of the EsVan model by removing 2 variables believed to be less reliable across larger multi-institutional populations would improve the predictive ability across external data sets while maintaining its performance on the initial Vanderbilt data set. The EsVan2 model was found to have a C statistic similar to that of the EsVan model when applied to the Vanderbilt data set, and indeed performed better when applied to the external data sets. Because some institutions cannot get an AMC result back in a timely fashion to incorporate it into a predictive model, a version of the EsVan2 model was created that removed the AMC. This model, EsVan2b, was found to decrease the predictive ability only slightly.
Because each of the individual data sets was small compared with the initial EsVan data set, the current analysis combined the external data into one large cohort. The model performed better in data sets that had higher rates of BSI (UCSF and Stanford) compared with those with low BSI rates (CHOP and Lebanon). To the best of our knowledge, it is not clear why the data set performed much worse in the CHOP data set, although it was the smallest; only contained a small percentage of patients treated during the given time period at CHOP; and had a surprisingly low BSI rate of 3%, with only 1 BSI found to be high-risk despite containing patients with a high rate of stem cell transplantation and external CVCs. This likely was due to a random case mix in a small data set but could be related to unknown factors such as infection control practices.
One limitation of the current study is that the variables were collected through retrospective chart review, and were limited by the quality of the data in the primary records. However, this is outweighed by validation of this model across different academic centers with diverse patient populations as well as antimicrobial and admission practices.
Incorporation of This Model
Because the EsVan2 model demonstrated the best overall discrimination and calibration, it is the model that will be moved forward in prospective trials. Because the majority of patients (85%) had a risk of <10%, this is a group that potentially could have initial empiric antibiotics withheld. Supporting this is the published data from Stanford University and included in the validation cohort indicating that well-appearing febrile pediatric oncology patients without severe neutropenia do well without the administration of empiric antibiotics. 3 For those at high-risk (predicted risk of > 40%), the original model actually may overpredict their risk slightly, which most likely indicates that some BSIs (particularly anaerobic ones) are culturenegative, as well as those with significant bacterial or viral illnesses without bacteremia; however, if an actual risk of a BSI is >40%, it is likely warranted that these subjects be treated more aggressively with antibiotics likely to cover the isolated BSI.
It must be emphasized that evidence-based risk prediction models never should be used to replace clinical judgment, but should be used as an aid to guide management. The practice of limiting antibiotics because of the model is not recommended for ill-appearing subjects with any concern of severe sepsis; however, the inclusion of these variables is important to help the precision of the model and to help identify subjects at high-risk that an individual may not initially identify that way. Similar caution also would be recommended for other high-risk groups such as subjects aged <1 year, those who are unreliable for follow-up, those with a rapidly falling ANC, or in patients after stem cell transplantation. It should be noted that the original model and this validation specifically were for BSI and other foci of infection should be treated independently of the BSI risk. However, with these important caveats, with the external validation of the EsVan predictive model, and with improvements noted with the EsVan2 predictive model, the EsVan2 model shows promise that it may be implemented to help guide management for the prediction of BSI in febrile pediatric oncology patients without severe neutropenia. Therefore, a prospective implementation trial is planned.
If shown to be effective prospectively, incorporation of the EsVan2 model into clinical practice has the potential to greatly impact antibiotic stewardship in pediatric oncology patients. For institutions that currently administer empiric antibiotics to all patients, empiric antibiotics potentially could be withheld among those determined to be at low risk of BSI, and in institutions that do not routinely administer empiric antibiotics to these subjects, the model potentially could help to identify those at high risk of BSI in whom empiric treatment would be warranted. Further prospective implementation will help to clarify these questions.
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